Peanut allergy therapy scores trial win, putting it in line to possibly become first protective treatment

An experimental treatment aimed at helping people with severe peanut allergy scored a clinical win Tuesday, putting it in line to possibly become the first drug to provide meaningful protection against accidental exposure.

Based on the positive results, Aimmune Therapeutics expects to seek U.S. approval for its preventative peanut allergy therapy by the end of the year, with a European filing in 2019, the company said.

Aimmune shares were up 11 percent to $41.19 in Tuesday morning trading.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

Already have an account? Log in

Individual plans

Group plans

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $399/year

$30 for 3 months Get Started

Then $399/year

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

To read the rest of this story subscribe to STAT+.

Subscribe

Log In